Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells $64,504.02 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes sold 4,578 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $64,504.02. Following the sale, the chief operating officer now owns 100,724 shares in the company, valued at $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Bicycle Therapeutics Stock Performance

BCYC stock opened at $14.17 on Thursday. The firm has a fifty day moving average price of $19.09 and a 200 day moving average price of $21.82. Bicycle Therapeutics plc has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The firm has a market cap of $978.38 million, a PE ratio of -4.31 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business’s revenue was down 50.0% on a year-over-year basis. During the same period last year, the company posted ($1.26) EPS. On average, equities analysts predict that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Analysts Set New Price Targets

BCYC has been the topic of a number of recent analyst reports. Stephens initiated coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target on the stock. JMP Securities lowered their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. B. Riley lowered their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently added to or reduced their stakes in BCYC. FMR LLC purchased a new position in shares of Bicycle Therapeutics in the 3rd quarter worth approximately $3,406,000. TD Asset Management Inc boosted its stake in Bicycle Therapeutics by 76.7% during the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after buying an additional 42,200 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Bicycle Therapeutics by 33.2% in the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after acquiring an additional 32,313 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Bicycle Therapeutics in the 3rd quarter worth about $10,028,000. Finally, State Street Corp boosted its stake in shares of Bicycle Therapeutics by 233.5% during the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock worth $1,952,000 after purchasing an additional 60,399 shares during the period. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.